Objectives: To assess the efficacy and safety of modified Xiaoyao San (XYS) for treating Perimenopausal syndrome (PMS). Methods: Literature searches were carried out on PubMed, Cochrane Library, CNKI Database, Chinese...Objectives: To assess the efficacy and safety of modified Xiaoyao San (XYS) for treating Perimenopausal syndrome (PMS). Methods: Literature searches were carried out on PubMed, Cochrane Library, CNKI Database, Chinese Biomedical Literature Database, Wan Fang Database, and VIP Database up to December 2018. Hand search for further references was conducted. Study selection, data extraction, quality assessment, and data analyses were performed as request of the Cochrane standards. Results: Nine publications in total were suitable for inclusion. There was evidence that modified XYS was tested to be more effective in improving overall symptoms compared with HRT (odds ratio 3.50, 95% CI 2.56 to 4.78). Whereas HRT was more sensitive and direct in decreasing FSH (WMD 6.69, 95% CI 5.60 to 9.52) and LH (WMD 7.00, 95% CI, 5.75 to 8.25) in comparison with XYS group. It was also strongly supported that XYS had less adverse effect than HRT (odds ratio 0.07, 95% CI 0.05 to 0.10). Conclusion: Modified XYS might be more effective and safer in treatment of perimenopausal syndrome. However, due to poor methodological quality in the majority of included studies, the potential benefit and safety about XYS need to be confirmed in rigorously designed, multi-centre, and large-scale trials.展开更多
文摘溃疡性结肠炎(ulcerative colitis,UC)是一种病因复杂且复发率高的慢性非特异性炎症性肠病。《2017年溃疡性结肠炎中西医结合诊疗共识意见》中将出自《证治准绳》的四神丸作为治疗脾肾阳虚型UC的基础中药方剂。以四神丸为主方加减化裁、联合其他中药复方、联合西药以及其他中医特色疗法治疗慢性复发性UC具有疗效确切、不良反应小、复发率低、多靶点及多通路调控等优势。调节免疫是四神丸治疗UC的主要作用机制,主要表现在对记忆性T细胞(Memory T cell,TM)、辅助型T细胞1(T helper 1 cell,Th1)/辅助型T细胞2(T helper 2 cell,Th2)、调节性T细胞(Treg)、辅助性T细胞17(T helper cell 17,Th17)、滤泡辅助性T细胞(follicular B helper T cells,Tfh)/滤泡调节性T细胞(follicu⁃lar regulatory T cells,Tfr)、树突状细胞、B淋巴细胞和肠道菌群等以及多条信号通路调控作用,显示出四神丸良好的免疫药理作用。因此,就近年来四神丸治疗UC的临床运用及免疫药理学研究展开综述,以期为中医药治疗UC提供更多思路和途径。
文摘Objectives: To assess the efficacy and safety of modified Xiaoyao San (XYS) for treating Perimenopausal syndrome (PMS). Methods: Literature searches were carried out on PubMed, Cochrane Library, CNKI Database, Chinese Biomedical Literature Database, Wan Fang Database, and VIP Database up to December 2018. Hand search for further references was conducted. Study selection, data extraction, quality assessment, and data analyses were performed as request of the Cochrane standards. Results: Nine publications in total were suitable for inclusion. There was evidence that modified XYS was tested to be more effective in improving overall symptoms compared with HRT (odds ratio 3.50, 95% CI 2.56 to 4.78). Whereas HRT was more sensitive and direct in decreasing FSH (WMD 6.69, 95% CI 5.60 to 9.52) and LH (WMD 7.00, 95% CI, 5.75 to 8.25) in comparison with XYS group. It was also strongly supported that XYS had less adverse effect than HRT (odds ratio 0.07, 95% CI 0.05 to 0.10). Conclusion: Modified XYS might be more effective and safer in treatment of perimenopausal syndrome. However, due to poor methodological quality in the majority of included studies, the potential benefit and safety about XYS need to be confirmed in rigorously designed, multi-centre, and large-scale trials.